Regeneron's SWOT analysis: stock faces eylea challenges amid pipeline promise
Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...
Ex-Trump official: H-1B system is proof that America’s schools need radical transformation
The U.S. grants about 65,000 regular H-1B visas annually, plus 20,000 more for foreigners with a graduate degree from a U.S.
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...
Ukraine war latest: Ukrainian drones hit Lukoil oil refinery, missile arsenal in Russia, sources claim
Russian Lukoil oil refinery struck by multiple Ukrainian drones, military intelligence source claims Russian assault ...
Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.